News & Views
Telix and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States…
Read more
Telix announces the oral presentation of Part 1 safety, dosimetry and pharmacokinetics data from the ProstACT Global Phase 3 Study of TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), in metastatic castration-resistant prostate…
Read more
News,
Craig Stankiewicz is a husband, father and business professional from Chicago, Illinois. In August 2021, Craig was diagnosed with glioblastoma (GBM) and almost five years on he continues to face…
Read more
News,
Join Telix at the 2026 ASCO Annual Meeting, taking place this week in Chicago. ASCO 2026 will feature a late-breaking oral presentation on safety and dosimetry results from Part 1 of…
Read more
News,
Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting. This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel…
Read more
News,
Telix advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies…
Read more
News,
Courtney Watson is the Director of Programs and Communications at Head for the Cure, a nonprofit organization dedicated to raising awareness and funding for the brain tumor community. Her mother,…
Read more
News,
Telix today announces that the IPAX-2 study[1] of TLX101-Tx (¹³¹I-iodofalan) in patients with newly diagnosed glioblastoma has completed patient enrolment. No dose-limiting toxicities (DLTs) have been observed to date, including…
Read more
News,
Telix today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A.(NASDAQ: EDAP, “EDAP”) and Profound Medical Corp. (NASDAQ: PROF, TSX: PRN, “Profound”), leading…
Read more
News,
Telix today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology, demonstrating that TLX250‑Px (Zircaix®, 89Zr-girentuximab) PET/CT imaging may be highly predictive…
Read more